Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Why Editas Medicine Stock Is Jumping Today
12:17pm, Monday, 28'th Jun 2021
Good news for Intellia was viewed as good news for Editas.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
10:36am, Monday, 28'th Jun 2021
So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.
Why Editas Medicine Stock Is Jumping 13.9% This Week
06:01am, Friday, 25'th Jun 2021
The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
12:02pm, Thursday, 24'th Jun 2021
Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.
IDMC endorsed proceeding with first pediatric cohort based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts
Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer
04:01pm, Tuesday, 15'th Jun 2021
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appoin
Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavio
Is Editas the Best Genetics Stock to Buy?
08:08am, Saturday, 05'th Jun 2021
There are some big opportunities in the gene editing space.
Editas: I Remain Wary Of The Entire Crispr Space
08:07am, Sunday, 16'th May 2021
Editas has gained and lost considerably since my previous coverage. They have a critical data announcement by year-end.
With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market
06:40am, Friday, 07'th May 2021
One company is setting itself apart in a crowded field.
What Really Mattered With Editas Medicine's Q1 Update
02:46pm, Wednesday, 05'th May 2021
It wasn't the biotech's financial performance.
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q1 2021 Results - Earnings Call Transcript
01:40pm, Wednesday, 05'th May 2021
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q1 2021 Results - Earnings Call Transcript
Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat
11:39am, Wednesday, 05'th May 2021
Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
09:24am, Wednesday, 05'th May 2021
Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Domino's, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls
12:16pm, Tuesday, 04'th May 2021
With the trading day more than halfway over, the broad markets were getting crushed.
